Synaptogenix Inc (SNPX)

[InTheTrenches]

I agree with the thread.

If Bryostatin only HALTS the progression of AD (safely) over the long haul, this will get bought out for $10B+

If Bryostatin consistently and safely IMPROVES the scores of AD patients AND treats some or all of the other diseases (Fragile-X, Niemann-Pick, TBI, MD, etc), the buyout price will be $20B+.

To be clear: there's still significant risk in NTRP, and it will take 3-5 years and a lot of work to get to either of these buyout prices. But if successful, the payday will be enormous.